Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02071199 · ClinicalTrials.gov registry record · Phase 1
Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS)
A Phase 1 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT02071199 is a Phase 1 study that has completed, run by Noveome Biotherapeutics, formerly Stemnion. The registered enrollment target is 54 participants.
The verdict
NCT02071199, a Phase 1 study, has completed, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of oral topical application of Amnion-derived Cellular Cytokine Solution (ACCS) in subjects with gingivitis
Interventions
- DRUG Normal saline
- DRUG 1X ACCS (Amnion-derived Cellular Cytokine Solution)
- DRUG 0.3X ACCS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02071199
The ClinicalTrials.gov registry entry for NCT02071199 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noveome Biotherapeutics, formerly Stemnion, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Normal saline is the first listed.
NCT02071199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02071199 about?
NCT02071199 is a clinical study titled "Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS)". The purpose of this study is to evaluate the safety of oral topical application of Amnion-derived Cellular Cytokine Solution (ACCS) in subjects with gingivitis
What is the current status of trial NCT02071199?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2014-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02071199?
The interventions under investigation include: Normal saline (DRUG), 1X ACCS (Amnion-derived Cellular Cytokine Solution) (DRUG), 0.3X ACCS (DRUG).
Who is sponsoring clinical trial NCT02071199?
This trial is sponsored by Noveome Biotherapeutics, formerly Stemnion, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.